Translational Genomics Research Institute, Phoenix, Arizona, United States of America.
PLoS One. 2013 Aug 15;8(8):e72134. doi: 10.1371/journal.pone.0072134. eCollection 2013.
Histology of malignant glioma depicts dense proliferative areas rich in angiogenesis as well as dissemination of neoplastic cells into adjacent brain tissue. Although the mechanisms that trigger transition from proliferative to invasive phenotypes are complex, the dichotomy of cell proliferation and migration, the "Go or Grow" hypothesis, argues for specific and coordinated regulation of these phenotypes. We investigated transcriptional elements that accompany the phenotypes of migration and proliferation, and consider the therapeutic significance of the "Go or Grow" hypothesis. Interrogation of matched core and rim regions from human glioblastoma biopsy specimens in situ (n = 44) revealed higher proliferation (Ki67 labeling index) in cells residing at the core compared to the rim. Profiling activated transcription factors in a panel of migration-activated versus migration-restricted GBM cells portrayed strong NF-κB activity in the migratory cell population. In contrast, increased c-Myc activity was found in migration-restricted proliferative cells. Validation of transcriptional activity by NF-κB- or c-Myc-driven GFP or RFP, respectively, showed an increased NF-κB activity in the active migrating cells, whereas the proliferative, migration restricted cells displayed increased c-Myc activity. Immunohistochemistry on clinical specimens validated a robust phosphorylated c-Myc staining in tumor cells at the core, whereas increased phosphorylated NF-κB staining was detected in the invasive tumor cells at the rim. Functional genomics revealed that depletion of c-Myc expression by siRNA oligonucleotides reduced cell proliferation in vitro, but surprisingly, cell migration was enhanced significantly. Conversely, inhibition of NF-κB by pharmacological inhibitors, SN50 or BAY-11, decreased both cell migration in vitro and invasion ex vivo. Notably, inhibition of NF-κB was found to have no effect on the proliferation rate of glioma cells. These findings suggest that the reciprocal and coordinated suppression/activation of transcription factors, such as c-Myc and NF-κB may underlie the shift of glioma cells from a "growing-to-going" phenotype.
恶性神经胶质瘤的组织学特征是密集的增殖区域,富含血管生成以及肿瘤细胞向邻近脑组织的扩散。虽然触发从增殖到侵袭表型转变的机制很复杂,但细胞增殖和迁移的二分法,即“生长或转移”假说,认为这些表型需要特定和协调的调控。我们研究了伴随迁移和增殖表型的转录因子,并考虑了“生长或转移”假说的治疗意义。对原位(n = 44)人胶质母细胞瘤活检标本的核心和边缘区域进行配对分析,发现核心区域的细胞增殖(Ki67 标记指数)高于边缘区域。在一组迁移激活型与迁移受限型 GBM 细胞中对激活转录因子进行分析,显示迁移细胞群体中 NF-κB 活性较强。相比之下,在迁移受限的增殖细胞中发现 c-Myc 活性增加。通过 NF-κB 或 c-Myc 驱动的 GFP 或 RFP 分别验证转录活性,显示活跃迁移细胞中 NF-κB 活性增加,而增殖、迁移受限的细胞显示 c-Myc 活性增加。对临床标本的免疫组织化学验证显示,核心区域的肿瘤细胞中存在强烈的磷酸化 c-Myc 染色,而边缘区域的侵袭性肿瘤细胞中检测到磷酸化 NF-κB 染色增加。功能基因组学显示,siRNA 寡核苷酸降低 c-Myc 表达可减少体外细胞增殖,但令人惊讶的是,细胞迁移显著增强。相反,通过药理学抑制剂 SN50 或 BAY-11 抑制 NF-κB 可减少体外细胞迁移和体外侵袭。值得注意的是,抑制 NF-κB 对神经胶质瘤细胞的增殖率没有影响。这些发现表明,转录因子(如 c-Myc 和 NF-κB)的相互和协调抑制/激活可能是神经胶质瘤细胞从“生长到转移”表型转变的基础。